What's New: July 2026 Update TRIUMPH-1 CONFIRMED (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients Eli Lilly's pivotal Phase 3 obesity trial met all primary and key secondary endpoints 45.3% of patients on 12mg lost 30% of body weight surgical-level outcomes confirmed in the largest retatrutide trial to date 104-week extension: patients with BMI 35 reached up to 30.3% average weight loss weight loss did not plateau at 80 weeks TRANSCEND-T2D-1 CONFIRMED (topline March 2026, published June 2026): First completed Phase 3 trial in type 2 diabetes up to -2.0% HbA1c reduction and 16.8% weight loss in 537 patients, a separate program from TRIUMPH OSA data confirmed (ADA June 6, 2026): TRIUMPH-1's nested sleep apnea substudy showed 60.6% AHI reduction from a baseline of 58.6 events/hour NDA on track: Industry estimates continue to expect Q4 2026 filing following TRIUMPH-1 and TRIUMPH-4 data TRIUMPH-2 and TRIUMPH-3 results still expected later in 2026 this page updates monthly Current Status: Where Things Stand Retatrutide is an investigational medication developed by Eli Lilly
Wipe the vial tops with alcohol, draw the right amount of bacteriostatic water, inject it slowly down the inside wall of the peptide vial, gently swirl until clear, then label and refrigerate
OTC patches have zero controlled data
Another important detail is that the GIP component may help improve tolerability for some patients compared to older GLP-1 medications alone
Your skin forms a protective barrier to prevent harmful pathogens and molecules from entering your body
These factors suggest that hair loss may not directly result from GLP-1 medications but rather from the changes they induce in your body, but more research is needed to fully understand the connection
